Abstract
Objective Anosmia has been listed as a key-symptom associated with the COVID-19 infection. Because it often occurs without any sign of rhinitis, lesions of the central olfactory system have been suspected. To date, however, there is no evidence that anosmia caused by SARS-CoV2 could be the result of brain damage.
Methods We conducted a case-series on 10 consecutive COVID-19 patients who reported anosmia. Each patient prospectively underwent a validated olfactory test (Sniffin’ Sticks test) and a brain MRI. Results Hypersignal intensity lesions of the central olfactory system were found in 3 subjects on 3D T2 FLAIR and 2D T2 High Resolution images with a lesion involving the olfactory bulbs and/or the orbitofrontal cortex. These 3 subjects showed a severe and persistent loss of smell on the olfactory test. Mucosal hyperplasia of the upper nasal cavities was found in two other subjects with significant smell disorders. There was no MRI anomaly in two subjects with good smell restoration.
Conclusions Anomalies of the central olfactory system could be responsible for anosmia in patients with COVID-19 infection. Further studies are needed to assess the impact on long-term functional prognosis of these lesions.
Key Result Central anomalies of the olfactory bulb and cortex could be responsible for anosmia in COVID-19 infection
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the Assistance Publique des Hopitaux de Paris - APHP
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB registration : #00011928 CERAPHP.5 Comite d'ethique de la recherche AP-HP.5 15 Rue de l'Ecole de Medecine, 75006 Paris Courriel : contact.ceraphp5@listes.parisdescartes.fr
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data generated and analyzed are available upon request from the corresponding author: Yannick Girardeau Hopital Europeen Georges Pompidou - DIH - 20 Rue Leblanc, 75015 Paris e-mail: yannick.girardeau@aphp.fr
Abbreviations
- COVID-19
- Coronavirus Disease 2019
- OB
- Olfactory Bulb
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus 2
